Market news

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.16% on an annualized basis producing an average annual return of 44.36%. Currently, Krystal Biotech has a market capitalization of

Krystal Biotech (KRYS) has an average rating of buy and mean price target of $386, according to anal

Krish S Krishnan, 10% Owner, Director, President and Chief Executive Officer, on September 04, 2026,

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In a sign of strength, IBKR continued rising in extended hours trading, climbing as high as 98.50 shortly after the close.

Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.

Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and crypto all at once.

Krystal Biotech (KRYS) has an average rating of buy and mean price target of $385, according to anal

Krystal Biotech (KRYS) has further room for gains driven by Vyjuvek, its treatment for the rare blis

VYJUVEK revenue surged 24% as the company eyes a multiproduct pipeline transition.

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.0% on an annualized basis producing an average annual return of 42.63%. Currently, Krystal Biotech has a market capitalization of

Krystal Biotech stock has delivered a very large 5 year return while recent valuation checks and the latest share price action suggest the current market price may already be baking in high expectations. Krystal Biotech has returned roughly 5x over the past 5 years, which puts extra focus on whether the current share price still offers an appealing entry point or mainly reflects past success. Ongoing adoption of its genetic medicine platform can support the current valuation, while concerns...

KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.

Moby summary of Krystal Biotech, Inc.'s Q2 2026 earnings call

Top-notch biotech stocks TG Therapeutics and Twist Bioscience diverged Monday on mixed earnings reports.

(Updates with the latest stock movement in the first paragraph and headline.) Krystal Biotech (KR

Krystal Biotech, Inc. (NASDAQ:KRYS) reported second-quarter 2026 results on Monday that exceeded earnings expectations but fell short of Wall Street’s revenue estimates, sending the stock down 7.

Krystal Biotech (KRYS) delivered earnings and revenue surprises of +5.29% and +0.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Krystal Biotech (NASDAQ:KRYS) reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for patients with dystrophic epidermolysis bullosa, or DEB, in the United States and overs

PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter...

$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in...

Krystal Biotech (KRYS) stock drew attention after the company disclosed new information related to KB801, its investigational gene therapy for neurotrophic keratitis, in a patent filing response with the U.S. Patent and Trademark Office. See our latest analysis for Krystal Biotech. Against this backdrop, Krystal Biotech’s share price has moved to US$363.28, with the stock up 7.86% over the past week and showing a 90 day share price return of 38.52%. The 1 year total shareholder return is...

Krystal Biotech earns a Strong Buy rating, driven by its fortress-like balance sheet, exceptional margins, and rapid Vyjuvek commercial success. Learn more about KRYS stock here.

Earlier this month, Krystal Biotech, Inc. was moved from the S&P 600 to the S&P 400, joining the S&P 400 Health Care and Biotechnology indices, and also filed a response with the U.S. Patent and Trademark Office that included single-patient data from its investigational KB801 gene therapy for neurotrophic keratitis. The company emphasized that the observed complete closure of a persistent corneal epithelial defect in one KB801-treated patient came from a discontinued study, carries no safety...

Detailed price information for CVS Corp (CVS-N) from The Globe and Mail including charting and trades.

Detailed price information for Humana Inc (HUM-N) from The Globe and Mail including charting and trades.

Detailed price information for Berkshire Hathaway Cl B (BRK-B-N) from The Globe and Mail including charting and trades.

S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600:

Motley Fool Press Release.